Advertisement
SPRY Novinky na Forexu
ARS Pharmaceuticals Says FDA Schedules Type A Meeting For Neffy By The End Of October
Biopharmaceutical company ARS Pharmaceuticals, Inc. (SPRY) announced Friday that the U.S. Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.
RTTNews
|
Před 672 dny
